Regenerative Medical Solutions Inc. (RMS)
- Home
- Companies
- Regenerative Medical Solutions Inc. ...
- Products
- RMS - Technology
RMS - Technology
Regenerative Medical Solutions (RMS) has developed a novel and proprietary technology to transform stem cells into insulin producing cells. Our pancreatic islet like cluster (ILC) cells are morphologically and functionally similar to β islet cells isolated from the human body. They contain glucagon producing alpha cells, somatostatin producing delta cells and insulin producing β islet cells.
Most popular related searches
pluripotent stem cell
stem cell
insulin producing
stem cell differentiation
insulin secreting
insulin secretion
pancreatic islets
pancreatic islet
therapeutic candidate
clinical development
We have leveraged our ILC technology to develop two product lines:
- ILC Cells– A specially formulated cryopreserved single cell ILC’s that can be used for diabetes research, drug discovery and toxicity testing.
- ILC cellular therapeutic candidate – Our diabetes cellular therapeutic that is under pre-clinical development.
RMS has built a substantial IP and know-how (trade secret) portfolio over the years in additional to exclusive and non-exclusive licensing of IP from academic institutions.
- Issued Patent (8,685,730): “Methods and Devices For Differentiating Pluripotent Stem Cells Into Cells Of The Pancreatic Lineage”
- Issued Patent (9,540,613 B2), RMS was a co-inventor with University of Wisconsin: “Methods For Producing Insulin-secreting Beta Cells From Human Pluripotent Stem Cells”
- Issued Patent (9,828,634): Markers for differentiation of stem cells into differentiated cell populations.
- Issued Patent (9,765,302): Compositions and methods for differentiating stem cells into cell. populations comprising beta-like cells.
- Non-exclusive license from Academia Japan to practice iPSC methods for both research tools and therapy.
